Celsion Corporation
Celsion Provides Update on Progress of ThermoDox(R) Phase III Study for Primary Liver Cancer
Published in Disease Risk Factor Week, December 20th, 2009
Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III "HEAT" trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.
Enrollment in this 600 patient study continues to accelerate and Celsion expects to meet its objective of completing enrollment by the middle of 2010. A...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Disease Risk Factor Week
More Articles from Disease Risk Factor Week
- Abdominal Aortic Aneurysm
Research reports from Johns Hopkins University provide new insights into abdominal aortic aneurysm - Acute Coronary Syndrome
Studies from University of Sheffield describe new findings in acute coronary syndrome - Age and Aging
Research on age and aging reported by scientists at University of Montreal - American Association for Cancer Research
Mexican-American youths' risk of experimenting with cigarettes depends on susceptibility - American College of Physicians
Role of evidence based medicine in clinical decision-making addressed by ACP in testimony - Aneurysm
Research conducted at C.J. Okelly and co-authors has provided new information about aneurysm - More from this issue of Disease Risk Factor Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
